REPL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
REPL is not a good buy right now. The primary trend remains bearish (SMA200 > SMA20 > SMA5) and price is below the pivot (7.358) after a -3.11% regular-session drop. While options positioning looks bullish (low put/call ratios) and the stock is near short-term oversold levels, there is no Intellectia buy signal today and no near-term news catalyst—so the setup favors continued weakness/chop rather than a high-confidence entry for an impatient buyer.
Trend/structure: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) signals a sustained downtrend. Momentum: MACD histogram is slightly positive (0.00138) but positively contracting, implying any bounce is losing steam rather than accelerating. RSI: RSI_6 at 30.698 is near oversold territory, supporting the idea of a short-term bounce risk, but not a confirmed reversal. Levels: Pivot 7.358 is immediate overhead resistance; supports at S1 6.922 and S2 6.653. Upside levels: R1 7.793 then R2 8.062. Pattern-based short-term outlook: Similar-pattern model suggests ~0.61% next day, -1.07% next week, -4.32% next month bias—skewed negative.
Intellectia Proprietary Trading Signals
Options positioning leans bullish (low put/call ratios), suggesting traders are not heavily hedging near-term downside.
with price below pivot resistance—trend traders will typically sell rallies.
Latest reported quarter: 2026/Q2. Revenue remained 0 (0.00% YoY), consistent with a pre-commercial biotech profile. Losses narrowed: Net income improved to -$83.1M (+56.63% YoY improvement), and EPS improved to -0.90 (+32.35% YoY improvement). This is a positive cost/loss trend, but the business still lacks revenue traction, leaving the stock primarily catalyst-driven (clinical/regulatory).
Recent analyst change: On 2025-11-03, BMO Capital upgraded REPL to Market Perform from Underperform and lifted its price target to $11 (from $2), citing that current levels reflect appropriate risk and that regulator alignment for RP1 improved after a productive Type A meeting. Wall Street pro view (pros): Improved regulatory clarity and a higher perceived probability of progress/approval pathway for RP1. Wall Street con view (cons): Rating is only Market Perform (not an outright Buy), implying upside may be balanced by execution/regulatory risks and ongoing losses. Influential/congress trading check: No recent congress trading data available; hedge fund and insider trends reported as neutral.
